Publications

Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, Shelton G, Feit K, Petrylak D, Nanus DM.  2002.  Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.. Cancer. 95(6):1220-7.

Zhan HChun, Gudas LJ, Bok D, Rando R, Nanus DM, Tickoo SK.  2003.  Differential expression of the enzyme that esterifies retinol, lecithin:retinol acyltransferase, in subtypes of human renal cancer and normal kidney.. Clin Cancer Res. 9(13):4897-905.

Boorjian S, Tickoo SK, Mongan NP, Yu H, Bok D, Rando RR, Nanus DM, Scherr DS, Gudas LJ.  2004.  Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.. Clin Cancer Res. 10(10):3429-37.

Touma SEllen, Goldberg JS, Moench P, Guo X, Tickoo SK, Gudas LJ, Nanus DM.  2005.  Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.. Clin Cancer Res. 11(9):3558-66.

Boorjian S, Scherr DS, Mongan NP, Zhuang Y, Nanus DM, Gudas LJ.  2005.  Retinoid receptor mRNA expression profiles in human bladder cancer specimens.. Int J Oncol. 26(4):1041-8.

Raman JD, Mongan NP, Liu L, Tickoo SK, Nanus DM, Scherr DS, Gudas LJ.  2006.  Decreased expression of the human stem cell marker, Rex-1 (zfp-42), in renal cell carcinoma.. Carcinogenesis. 27(3):499-507.

Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MVallee, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ et al..  2007.  Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.. J Immunother. 30(6):655-62.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM.  2010.  Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.. Cancer Biol Ther. 9(9):678-84.

Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ.  2011.  Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.. Cancer Res. 71(21):6848-56.

Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ.  2013.  Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.. Cancer Res. 73(9):2916-25.

Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM.  2014.  The role of HIF1α in renal cell carcinoma tumorigenesis.. J Mol Med (Berl). 92(8):825-36.

Minton DR, Fu L, Chen Q, Robinson BD, Gross SS, Nanus DM, Gudas LJ.  2015.  Analyses of the transcriptome and metabolome demonstrate that HIF1α mediates altered tumor metabolism in clear cell renal cell carcinoma.. PLoS One. 10(4):e0120649.

Fu L, Minton DR, Zhang T, Nanus DM, Gudas LJ.  2015.  Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.. Mol Cancer Res. 13(5):870-8.

Minton DR, Fu L, Mongan NP, Shevchuk MM, Nanus DM, Gudas LJ.  2016.  Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.. Clin Cancer Res. 22(11):2791-801.

Nanus DM, Gudas LJ.  2016.  The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma.. Eur Urol. 69(4):658-659.

van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.

Orfali N, O'Donovan TR, Cahill MR, Benjamin D, Nanus DM, McKenna SL, Gudas LJ, Mongan NP.  2020.  All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).. Eur J Haematol. 104(3):236-250.

van der Mijn JC, Fu L, Khani F, Zhang T, Molina AM, Barbieri CE, Chen Q, Gross SS, Gudas LJ, Nanus DM.  2020.  Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma.. Transl Oncol. 13(2):177-185.

Molina AM, van der Mijn JC, Christos P, Wright J, Thomas C, Dutcher JP, Nanus DM, Tagawa ST, Gudas LJ.  2020.  NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.. Invest New Drugs.

Laursen KB, Chen Q, Khani F, Attarwala N, Gross SS, Dow L, Nanus DM, Gudas LJ.  2021.  Mitochondrial Ndufa4l2 Enhances Deposition of Lipids and Expression of Ca9 in the TRACK Model of Early Clear Cell Renal Cell Carcinoma.. Front Oncol. 11:783856.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, Oromendia C, Gudas LJ, Tagawa ST, Nanus DM et al..  2022.  The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. Mol Oncol.

van der Mijn JC, Chen Q, Laursen KB, Khani F, Wang X, Dorsaint P, Sboner A, Gross SS, Nanus DM, Gudas LJ.  2022.  Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).. Mol Carcinog.

Kubala JM, Laursen KB, Schreiner R, Williams RM, van der Mijn JC, Crowley MJ, Mongan NP, Nanus DM, Heller DA, Gudas LJ.  2023.  NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.. Cancer Biol Ther. 24(1):2170669.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, Chen Q, Gross SS, Nanus DM, Gudas LJ.  2023.  Novel genetically engineered mouse models for clear cell renal cell carcinoma.. Sci Rep. 13(1):8246.